SCHEMBL4924745

SCHEMBL4924745

COC(=O)c1cc(OCc2ccccc2)cc(OC(C)(C)O)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.58
HPGD P15428 1/20 0.58
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
MRGPRX4 Q96LA9 2/20 0.51
HIF1A Q16665 1/20 0.49
MAOB P27338 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.48
NR4A2 P43354 3/20 0.48
SMPD1 P17405 1/20 0.47
GCK P35557 1/20 0.46
PTPN1 P18031 1/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
PDK1 Q15118 1/20 0.45
PDK2 Q15119 1/20 0.45
PDK3 Q15120 1/20 0.45
PDK4 Q16654 1/20 0.45
NR4A1 P22736 2/20 0.44
NR4A3 Q92570 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL391547 0.89 MEN1 (0.71) LMNAHPGDMEN1KMT2AMRGPRX4
SCHEMBL2656457 0.89 LMNA (0.56) LMNAHPGDMEN1KMT2AMRGPRX4
SCHEMBL183994 0.86 LMNA (0.70) LMNAHPGDMEN1KMT2AMRGPRX4
SCHEMBL340311 0.85 LMNA (0.65) LMNAHPGDMEN1KMT2AMRGPRX4
SCHEMBL29788280 0.85 LMNA (0.65) LMNAHPGDMEN1KMT2AMRGPRX4
SCHEMBL90412 0.85 LMNA (0.69) LMNAHPGDMEN1KMT2AMRGPRX4
SCHEMBL29475634 0.85 LMNA (0.69) LMNAHPGDMEN1KMT2AMRGPRX4
SCHEMBL2657064 0.83 LMNA (0.51) LMNAHPGDMEN1KMT2AMRGPRX4
SCHEMBL3129603 0.82 MEN1 (0.74) LMNAHPGDMEN1KMT2AMRGPRX4
SCHEMBL2657646 0.82 LMNA (0.49) LMNAHPGDMEN1KMT2AMRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080234273-A1 Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes ASTRAZENECA AB (SE) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234273-A1 Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes GCK, GCKR, HK1 LMNA 3205/4885HPGD 398/4885MEN1 2322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.